TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

SLS009 exhibits favorable data in R/R lymphomas: topline results from phase I dose escalation trial.

By Kreena Mistry

Share:

Sep 25, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma.


Topline results obtained from a phase I dose escalation trial (NCT04588922) show that primary and secondary endpoints in safety, clinical activity, pharmacokinetics, and pharmacodynamics were met in patients with relapsed/refractory (R/R) lymphomas.1 These results indicate that SLS009 (formerly GFH009) may be a safe and efficacious treatment option for this patient population.1

Key findings1

A total of 52 R/R patients with lymphoma were enrolled and 34 patients were evaluable for efficacy. In this population:

  • In total, 14.7% achieved a clinical response, with a reduction in tumor burden of up to 62%.
  • Seven patients (20.6%) achieved stable disease, leading to an overall disease control rate of 35.3%.
  • Among the patients who had peripheral T-cell lymphoma, four out of 11 patients (36.4%) achieved clinical response.

No patients had unexpected toxicities and the drug was well tolerated, with no drug-related deaths reported at any dose level.

  • Patients receiving once-weekly infusions had ≥Grade 3 treatment-related adverse events which occurred at higher dose regimens.
  • Non-hematologic toxicities occurred in five patients (9.6%), of whom 5.8% experienced hypokalemia, 1.9% experienced upper respiratory tract infection, and 1.9% experienced increase in bilirubin.
  • Maximum tolerated dose was not reached.

The topline data from this phase I dose-escalation trial have led to a phase II clinical study. This study will assess SLS009 in patients with peripheral T-cell lymphoma, further elucidating the potential of this treatment for those with hematologic malignancies who have exhausted previous treatment options.1

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...